Hubbry Logo
ESCAPPMESCAPPMMain
Open search
ESCAPPM
Community hub
ESCAPPM
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
ESCAPPM
ESCAPPM
ESCAPPM
View on Wikipedia
from Wikipedia

ESCAPPM or ESCHAAPPM is a mnemonic for the organisms with inducible beta-lactamase activity that is chromosomally mediated.[1]

In vitro sensitivities are not applicable in vivo.

In general, treatment with cephalosporins results in induction of AmpC beta-lactamase.[2] Treatment with an aminoglycoside or carbapenem is usually indicated. Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity. They have a structure that renders them highly resistant to beta-lactamases. Examples of carbapenems include meropenem and imipenem.

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

ESCAPPM

View on Grokipedia
from Grokipedia
ESCAPPM is a mnemonic in clinical microbiology denoting a group of Gram-negative bacteria that produce inducible chromosomal AmpC β-lactamases, enzymes conferring resistance to β-lactam antibiotics such as penicillins and cephalosporins. The acronym expands to Enterobacter spp., Serratia spp., Citrobacter freundii, Acinetobacter spp., Proteus vulgaris, Providencia spp., and Morganella morganii. These organisms are primarily members of the family, except for Acinetobacter spp., and are notable for their role in nosocomial infections, including bacteremia, , and urinary tract infections. The AmpC β-lactamases they harbor are typically repressed but can be induced by exposure to β-lactam antibiotics, leading to high-level resistance during therapy; for instance, treatment with third-generation cephalosporins like ceftazidime can select for resistant mutants in up to 19% of Enterobacter infections. This inducible resistance mechanism hydrolyzes cephalosporins and other β-lactams but spares and , making alternative agents like or aminoglycosides preferable for empirical treatment in high-risk settings. Clinically, ESCAPPM organisms pose challenges in antimicrobial stewardship due to their potential for emerging resistance, particularly in intensive care units where they contribute to multidrug-resistant infections. Detection relies on phenotypic tests, such as the induction of resistance in susceptibility assays, though plasmid-mediated AmpC variants can complicate identification in non-ESCAPPM species like . Understanding this group aids in guiding therapy to prevent treatment failure and reduce mortality associated with resistant Gram-negative .

Overview

Definition and Mnemonic

ESCAPPM is an employed in clinical and infectious disease practice to denote a group of characterized by their potential for chromosomally mediated inducible AmpC production, which can confer resistance to beta-lactam antibiotics during therapy. This mnemonic aids clinicians and microbiologists in promptly recognizing these organisms, facilitating informed selection to mitigate the risk of treatment failure due to emerging resistance. The acronym expands to Enterobacter spp., Serratia spp., Citrobacter freundii, Acinetobacter spp., Proteus vulgaris, Providencia spp., and Morganella morganii. Derived from the initial letters of these genera, ESCAPPM highlights key producers of AmpC enzymes, emphasizing their clinical relevance in infections where beta-lactam stability is critical. Variations in the mnemonic exist to accommodate additional or context-specific organisms; for instance, some sources include Hafnia alvei as ESCHAPPM, while others simplify to ESCPM by focusing on core without Acinetobacter spp. in certain guidelines.

Historical Development

The ESCAPPM mnemonic emerged during the late and early amid growing clinical concerns over treatment failures attributed to AmpC derepression in hospital-acquired infections, particularly cases. Early reports highlighted the risk of inducible resistance developing during with third-generation cephalosporins, prompting the need for targeted organism groupings to guide selection in vulnerable settings like pediatric and adult wards. A key early reference appeared in a 2002 study on Gram-negative bacteremia in children, which introduced the similar "ESCaPPM" acronym (Enterobacter spp., Serratia spp., Citrobacter spp., Providencia spp., Morganella spp.) to denote organisms prone to beta-lactam resistance emergence, observed in approximately 5% of treated cases with potential for adverse outcomes. This reflected broader patterns in antimicrobial stewardship discussions, where such groupings helped clinicians anticipate derepressed mutants in nosocomial pathogens. The mnemonic evolved from prior focuses on extended-spectrum (ESBL) producers to emphasize chromosomal AmpC specifically, distinguishing stable basal expression from inducible hyperproduction under pressure. By the 2010s, ESCAPPM gained traction in educational materials, with resources like Deranged Physiology and LITFL incorporating it to aid recognition of high-risk organisms in intensive care and emergency contexts. underscored its relevance, revealing rising AmpC-mediated resistance in ICUs, including emergence rates of 8-19% during therapy for infections, often linked to prior exposure. Adoption into medical training curricula solidified around 2010, as the appeared in intensive care and modules, with regional adaptations such as expanded inclusion in tropical settings to account for local .

Constituent Organisms

Enterobacteriaceae Representatives

The representatives in the ESCAPPM mnemonic include several genera known for their production of inducible chromosomal AmpC β-lactamases, which confer resistance to β-lactam antibiotics. These organisms are significant in clinical settings due to their role in nosocomial infections and their potential for developing multidrug resistance through AmpC hyperproduction. Enterobacter spp. primarily encompass and (formerly Enterobacter aerogenes), which are ubiquitous in environmental reservoirs such as , , , and decaying . These facultative anaerobes are frequent causes of hospital-acquired infections, including bacteremia, , and urinary tract infections, particularly in immunocompromised patients and those with indwelling devices. The chromosomal ampC gene in these species exhibits strong inducibility, leading to elevated β-lactamase production upon exposure to cephalosporins, which can result in treatment failure with third-generation cephalosporins. Serratia spp., most notably , are opportunistic pathogens that predominantly affect immunocompromised individuals, causing infections such as urinary tract infections, respiratory tract infections, and bacteremia in hospital environments. This species is distinguished by its production of , a that aids in identification and may contribute to . S. marcescens harbors a chromosomal ampC with high baseline expression and strong inducibility, often leading to multidrug resistance profiles that complicate therapy in nosocomial outbreaks. is associated with , urinary tract infections, and , particularly in vulnerable populations like neonates and the elderly. It is commonly implicated in severe infections due to its environmental persistence in and . The chromosomal ampC gene is universally present, with potential for derepression and hyperproduction under antibiotic selective pressure, enhancing resistance to cephalosporins. , , and Providencia spp., including and , are urease-positive, motile rods that frequently cause catheter-associated urinary tract infections and wound infections in hospitalized patients. These organisms thrive in urinary environments due to their urease activity, which alkalinizes and promotes stone formation. P. vulgaris and M. morganii consistently produce inducible AmpC β-lactamase, while P. rettgeri shows variable AmpC expression, contributing to resistance emergence during prolonged . These share key traits as facultative anaerobes that are oxidase-negative and constituents of the normal human gut flora, though they represent a minor proportion (<1%) in healthy individuals. Their epidemiology highlights a higher prevalence in hospital settings, where they are significant contributors to Gram-negative bacteremia cases, driven by factors like antibiotic exposure and invasive procedures. This ecological niche facilitates transmission and selection for AmpC-mediated resistance.

Non-Enterobacteriaceae Members

The non-Enterobacteriaceae member in the ESCAPPM mnemonic is Acinetobacter spp., which are environmentally sourced, non-fermentative pathogens distinct from the typical gut-associated Enterobacteriaceae. Acinetobacter baumannii is the most clinically relevant species, commonly found in soil, water, and healthcare environments, serving as an opportunistic pathogen in hospitalized patients. These organisms primarily cause ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and wound infections, particularly in intensive care units, where they can lead to outbreaks of multidrug-resistant strains. The AmpC β-lactamase in Acinetobacter is chromosomally encoded in certain species and exhibits constitutive or inducible expression upon exposure to β-lactam antibiotics, conferring resistance to cephalosporins and complicating empirical therapy. Epidemiologically, Acinetobacter infections are linked to healthcare settings, accounting for 1-3% of nosocomial Gram-negative infections worldwide, with higher rates in regions with high antibiotic use. Unique biochemical features distinguish these organisms from core Enterobacteriaceae: Acinetobacter spp. are oxidase-negative, non-motile coccobacilli that grow well at 37–42°C, reflecting their adaptation to human-associated niches. Although they can harbor plasmids conferring additional resistance determinants like extended-spectrum β-lactamases or carbapenemases, the primary mechanism of AmpC-mediated resistance remains chromosomal, emphasizing their inherent potential for inducible β-lactam hydrolysis over acquired plasmid dissemination.

Resistance Mechanism

Inducible AmpC Beta-Lactamase

Inducible AmpC β-lactamases are class C enzymes in the Ambler molecular classification system, characterized by a serine-based active site that facilitates nucleophilic attack on the β-lactam ring of antibiotics. These enzymes feature a conserved catalytic triad and structural motifs such as the SXXK motif at position 64, which is essential for acylation during hydrolysis. In ESCAPPM organisms, AmpC hydrolyzes penicillins and cephalosporins up to the third generation, including cefotaxime and ceftazidime, but exhibits poor activity against carbapenems and fourth-generation cephalosporins like cefepime due to steric hindrance and lower affinity at the active site. The genetic basis of AmpC production primarily in the Enterobacteriaceae members of ESCAPPM (such as Enterobacter spp., Serratia spp., Citrobacter freundii, Proteus vulgaris, Providencia spp., and Morganella morganii) involves a chromosomally encoded ampC gene, typically located downstream of the regulatory ampR gene, which is divergently transcribed. In Acinetobacter spp., AmpC regulation occurs via alternative mechanisms without an ampR gene, often involving mutations that lead to overexpression. Under basal conditions, AmpR acts as a repressor by binding to the ampC promoter region, maintaining low-level expression; however, exposure to β-lactams derepresses the system, resulting in a 100- to 1000-fold increase in AmpC expression through enhanced transcription. This induction process begins when β-lactam antibiotics bind to the AmpR regulator—a LysR-type transcriptional activator—inducing a conformational change that promotes ampC transcription; the resulting stable mRNA leads to hyperproduction of the enzyme during antibiotic therapy. AmpC enzymes demonstrate broad substrate specificity within the β-lactam class but are ineffective against monobactams such as aztreonam, which lack the structural features required for efficient binding and hydrolysis. Beta-lactamase inhibitors like clavulanate show poor affinity for AmpC due to the enzyme's active site geometry, rendering them ineffective at restoring susceptibility to hydrolyzed antibiotics. The hydrolysis kinetics follow standard enzyme-substrate interactions, where the rate of β-lactam hydrolysis at substrate saturation is given by: Rate=kcat×[AmpC]\text{Rate} = k_{\text{cat}} \times [\text{AmpC}]

Clinical Emergence of Resistance

In ESCAPPM organisms, which harbor inducible chromosomal AmpC β-lactamases, initial in vitro susceptibility to third-generation cephalosporins such as ceftriaxone often masks the potential for derepression, where stable mutants overproduce the enzyme under selective pressure from β-lactam therapy. This leads to resistance emergence in approximately 10% of treated cases on average, rising to 20% in bacteremia, typically within a median of 7 days of therapy initiation. Key risk factors for derepression include prolonged monotherapy with third-generation cephalosporins, high-inoculum infections such as those in deep-seated or intra-abdominal sites, and prior exposure to antibiotics. These risks are amplified in critically ill patients, particularly those on mechanical ventilation or with biliary tract sources. Clinical studies report failure rates of 5-15% in Enterobacter bacteremia treated with cephalosporins due to AmpC derepression, while Serratia marcescens infections show lower emergence rates around 7%, though biofilms in these cases can enhance bacterial survival and persistence under therapy. Derepression is associated with severe consequences, including increased mortality up to 26% in affected cases compared to 13% in susceptible ones, as well as prolonged hospitalization by an average of 9 days. Plasmid-mediated AmpC spread is rare in ESCAPPM, with chromosomal mutations providing stable, persistent resistance. A representative example involves Citrobacter freundii urinary tract infection initially treated with ceftazidime, where derepression caused the minimum inhibitory concentration (MIC) to rise from <1 mg/L to >64 mg/L, resulting in therapeutic failure.

Clinical and Therapeutic Implications

Associated Infections

ESCAPPM organisms are opportunistic pathogens that primarily cause infections in healthcare settings, particularly among vulnerable populations such as the elderly, immunocompromised individuals undergoing or , and neonates. These bacteria are responsible for a range of nosocomial infections, often linked to invasive devices like catheters, ventilators, and surgical wounds. Common infection sites include urinary tract infections (UTIs), which are frequently associated with indwelling catheters, especially involving and Morganella species. Intra-abdominal infections, such as , are commonly caused by species, while respiratory tract infections like are often due to species. Certain demographics face heightened risks; for instance, species are a notable cause of , with mortality rates of 20-30% and significant neurological sequelae in survivors. factors such as adhesins for tissue attachment and toxins like the produced by contribute to disease severity, facilitating invasion and tissue damage. Globally, infection rates are higher in developing regions due to poorer and higher . These patterns underscore the opportunistic nature of ESCAPPM organisms, where resistance emergence in such settings can exacerbate outcomes. spp., unlike the Enterobacteriaceae members, often exhibit broader multidrug resistance, necessitating tailored approaches.

Antibiotic Selection and Alternatives

For empirical therapy in suspected infections involving ESCAPPM organisms, second- and third-generation cephalosporins such as and ceftazidime should be avoided due to the high risk of inducible AmpC expression leading to treatment failure. Instead, like (1 g IV every 8 hours) or beta-lactam/ inhibitor combinations such as piperacillin-tazobactam (4.5 g IV every 6 hours) are preferred for broad-spectrum coverage, particularly in severe or hospital-acquired cases, pending susceptibility results and local resistance patterns. Once ESCAPPM infection is confirmed through and susceptibility testing, should prioritize agents with lower induction potential. Cefepime, a fourth-generation , is often the first-line choice at high doses (e.g., 2 g IV every 8 hours with extended infusion) for susceptible strains across and species, as it demonstrates stability against AmpC . Aminoglycosides such as gentamicin (5-7 mg/kg IV daily) or serve as effective alternatives, especially for urinary tract infections or as adjunctive therapy in non-urinary sites. Fluoroquinolones like (400 mg IV every 12 hours) or levofloxacin may be used for step-down oral therapy in uncomplicated cases if susceptibility is confirmed, though resistance rates exceed 20% in many settings. In infections, sulbactam-based regimens (e.g., ampicillin-sulbactam at 3 g/1.5 g IV every 6 hours or sulbactam-durlobactam 1 g/1 g IV every 6 hours) are recommended when susceptible. Antimicrobial stewardship principles are crucial to mitigate resistance emergence in ESCAPPM infections. Short treatment courses of less than 7 days are advised for most cases to minimize selective pressure for AmpC derepression, with de-escalation to narrower agents based on clinical response and susceptibility. In severe infections, such as bloodstream or , combination therapy (e.g., beta-lactam plus ) is recommended initially to broaden coverage and reduce the risk of resistance development during treatment. Rapid susceptibility testing, including for newer agents, should guide all decisions to avoid unnecessary broad-spectrum use. For multidrug-resistant ESCAPPM strains, alternatives include (100 mg IV loading dose, then 50 mg every 12 hours) for intra-abdominal infections caused by or , due to its activity against AmpC producers despite limited tissue penetration elsewhere. (loading dose 9 million IU, then 4.5 million IU every 12 hours IV) or polymyxin B is reserved as a last-resort option for extensively drug-resistant cases, particularly carbapenem-resistant A. baumannii, though limits its use and resistance is emerging in up to 5-10% of hospital isolates in high-prevalence areas. These recommendations align with the Infectious Diseases Society of America (IDSA) 2024 guidance on antimicrobial-resistant Gram-negative infections and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint tables, which emphasize susceptibility testing prior to use and to preserve efficacy against AmpC producers.

Detection Methods

Phenotypic Approaches

Phenotypic approaches to detecting ESCAPPM organisms and their AmpC production rely on observable characteristics from culture, biochemical reactions, and susceptibility patterns, enabling identification in routine clinical laboratories without molecular tools. ESCAPPM organisms, comprising spp., Serratia spp., , Acinetobacter spp., , Providencia spp., and , are initially isolated on standard media such as , where lactose fermentation (or lack thereof) provides preliminary clues. Identification proceeds through biochemical tests tailored to family-specific traits. For Enterobacteriaceae members (Enterobacter, Serratia, Citrobacter freundii, Morganella, Providencia, Proteus vulgaris), the IMViC battery is foundational: Enterobacter typically shows indole-negative, methyl red-negative, Voges-Proskauer-positive, and citrate-positive reactions; Serratia often exhibits indole-negative, methyl red-negative, Voges-Proskauer-positive, and citrate-positive patterns, with some strains producing red prodigiosin pigment on nutrient agar; Citrobacter freundii displays variable IMViC results but is distinguished by citrate utilization and slow lactose fermentation; Morganella is indole-positive with swarming motility on agar; Providencia shows variable indole production alongside motility; and Proteus vulgaris is indole-positive, urease-positive, and produces hydrogen sulfide. Non-Enterobacteriaceae like Acinetobacter are oxidase-negative, non-motile, and non-fermentative. These tests, often automated via systems like VITEK or API 20E, confirm species identity within 24-48 hours post-culture. Susceptibility testing forms the cornerstone for inferring AmpC production, using disk or to determine minimum inhibitory concentrations (MICs) per Clinical and Laboratory Standards Institute (CLSI) guidelines. A key indicator is resistance to (zone diameter ≤18 mm by disk ), which screens for AmpC due to its by the , while zones for ceftazidime may remain larger (susceptible or intermediate) in inducible strains, reflecting partial stability against third-generation cephalosporins. resistance (zone ≤16 mm) offers higher specificity but lower sensitivity as a screener. These patterns—resistance to cephamycins like but variable susceptibility to cefepime and —prompt further AmpC confirmation, with overall screening sensitivity around 97% for but specificity of 79%. Induction and confirmation tests enhance specificity by exploiting AmpC inhibition. The cefoxitin-cloxacillin double-disk synergy test places a cloxacillin disk (200 μg) midway between cefoxitin (30 μg) and ceftazidime (30 μg) disks on Mueller-Hinton agar; a ≥4 mm increase in the ceftazidime inhibition zone due to cloxacillin's competitive inhibition of AmpC yields a positive result, with 97% sensitivity and 100% specificity. A variant of the Hodge test for AmpC uses a central cefoxitin disk surrounded by the test strain and indicator organism (e.g., E. coli ATCC 25922); a cloverleaf distortion of the inhibition zone indicates enzyme transfer and activity. The AmpC Etest employs cefotetan gradient strips with and without cloxacillin overlay; a ≥3 twofold dilution reduction in MIC (or "phantom zone") confirms production, achieving 77% sensitivity and 100% specificity. These tests simulate induction, revealing MIC creep (e.g., cefotetan MIC rising from 4 to 32 μg/mL post-inducer exposure in Enterobacter cloacae), but require 24-48 hour incubation.00053-2) As of 2024, innovative colorimetric tests like the Beta-LACTA test enable rapid (under 30 minutes) detection of AmpC production without distinction from other beta-lactamases, aiding preliminary screening in resource-limited settings. Despite their accessibility, phenotypic methods have limitations, including 70-90% overall specificity across tests due to interference from extended-spectrum beta-lactamases or porin loss, and false negatives in low-expression or stably derepressed strains where zones appear susceptible. No CLSI-endorsed confirmatory criteria exist, necessitating correlation with organism identity (e.g., presumptive AmpC risk in showing resistance). Turnaround remains 24-48 hours, suitable for routine use but slower than genotypic alternatives in outbreaks.

Genotypic Techniques

Genotypic techniques for detecting the ampC gene and its regulators in ESCAPPM organisms provide precise molecular confirmation of chromosomal AmpC production, aiding in epidemiological surveillance and differentiation from plasmid-mediated variants. (PCR) assays, particularly multiplex formats, target conserved regions of the chromosomal ampC gene prevalent in , , , and related genera. For instance, primers such as TN5 (5'-CGTTTGTCAGGCACAGTCAAATCCA-3') and TN4 (5'-TTACTGTAGCGCGTCGAGGATATGG-3') amplify the full of the ampC gene in isolates, enabling detection in clinical samples with high reliability due to sequence conservation across . These assays identify the presence of the gene in over 90% of suspected ESCAPPM strains, complementing phenotypic methods by confirming genetic basis without relying on induction. DNA sequencing of the ampC and associated regulators offers detailed of that enhance expression, such as those in promoter regions or regulatory genes like ampR in . Full sequencing reveals variants like point in ampD or ampR that lead to derepressed AmpC production, as observed in where such alterations correlate with stable resistance phenotypes. In species, sequencing the intergenic region between ampC and ampR identifies promoter responsible for elevated basal expression levels. This approach is particularly valuable for tracking evolutionary changes in resistance mechanisms within ESCAPPM populations. Advanced genotypic methods include real-time quantitative PCR (qPCR) for measuring ampC gene copy number and expression levels in ESCAPPM organisms. Whole-genome sequencing (WGS) facilitates outbreak tracing by resolving clonal relationships, such as in Providencia and isolates harboring chromosomal ampC, enabling identification of transmission chains in settings. For example, WGS has delineated Providencia clones in nosocomial infections, linking ampC variants to specific outbreaks. These techniques offer advantages including high specificity (approximately 95%) for chromosomal ampC detection and rapid turnaround times of 4-6 hours for PCR-based assays, allowing distinction between inherent chromosomal genes and acquired plasmid-mediated ones through sequence-specific targeting. Applications encompass in endemic regions, where costs range from $50-100 per test, and have become increasingly routine in clinical laboratories since 2015 for guiding control in ESCAPPM-related cases.

References

  1. https://www.publish.csiro.au/ma/ma09208
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2620637/
  3. https://litfl.com/multi-resistant-organisms-mros/
  4. https://derangedphysiology.com/main/required-reading/sepsis-and-infections/Chapter-412/acronymous-organisms-escappm-and-hacek
  5. https://cdstest.net/manual/gram-negatives/
  6. https://pubmed.ncbi.nlm.nih.gov/12394816/
  7. https://litfl.com/escaping-bugs/
  8. https://academic.oup.com/jac/article/73/6/1530/4939531
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC6750132/
  10. https://journals.asm.org/doi/10.1128/cmr.00002-19
  11. https://journals.asm.org/doi/10.1128/cmr.00017-11
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11731968/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC1153749/
  14. https://emedicine.medscape.com/article/222443-overview
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC11510300/
  16. https://www.ncbi.nlm.nih.gov/books/NBK442017/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC10967970/
  18. https://www.ncbi.nlm.nih.gov/books/NBK559296/
  19. https://journals.asm.org/doi/10.1128/cmr.00039-09
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC7038296/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC101621/
  22. https://www.sciencedirect.com/science/article/pii/S0923250820300139
  23. https://journals.asm.org/doi/10.1128/cmr.00036-08
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC6763639/
  25. https://journals.asm.org/doi/10.1128/jcm.00062-06
  26. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/214722
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC2258504/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC90703/
  29. https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-022-01079-5
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC9672193/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC9826615/
  32. https://www.researchgate.net/publication/333329951_Effect_of_ampC_derepression_on_cefepime_MIC_in_Enterobacterales_with_chromosomally_encoded_inducible_AmpC_b-lactamase
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC11117271/
  34. https://www.ncbi.nlm.nih.gov/books/NBK8035/
  35. https://emedicine.medscape.com/article/216845-treatment
  36. https://www.uptodate.com/contents/infections-due-to-serratia-species
  37. https://www.cmaj.ca/content/193/41/e1592
  38. https://publications.aap.org/pediatrics/article/118/5/e1576/69898/Diffuse-Pneumocephalus-in-Neonatal-Citrobacter
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC4248818/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10410267/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC8820817/
  42. https://www.sciencedirect.com/science/article/pii/S143846392200089X
  43. https://www.idsociety.org/globalassets/idsa/practice-guidelines/amr-guidance/4.0/amr-guidance-4.0.pdf
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC11417830/
  45. https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/clinical-breakpoint-tables/
  46. https://doi.org/10.1128/CMR.00036-08
  47. https://doi.org/10.1093/cid/ciz173
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC11494114/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC375280/
  50. https://academic.oup.com/jac/article/51/4/791/745218
  51. https://www.nature.com/articles/s41598-023-50685-1
  52. https://journals.asm.org/doi/10.1128/aac.01729-15
  53. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034067
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC11059591/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC11117914/
  56. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150643
Add your contribution
Related Hubs
User Avatar
No comments yet.